Strategic Partnerships ANGLE has a track record of collaborations with large pharma and genetics firms, including AstraZeneca and Myriad Genetics. Sales opportunities exist in expanding co-development and contract research collaborations for liquid biopsy workflows, assay development, and clinical trial testing services.

Clinical Diagnostics Expansion With FDA cleared Parsortix system and a growing clinical services arm in the UK and US, there is potential to upsell diagnostic consumables, workflows, and cloud-enabled data analysis services to hospitals and reference labs aiming to integrate CTC-based testing into standard oncology care.

Glioblastoma Focus Recent data presentations on glioblastoma PoC suggest a niche opportunity to target neuro-oncology programs and research consortia seeking liquid biopsy solutions for CNS tumors, offering tailored assay development and clinical trial testing.

Publicity and Thought Leadership Active engagement in conferences such as ACTC and EACR positions ANGLE to attract researchers and biotech buyers. Leverage events to generate outbound opportunities for pilot studies, non-dilutive collaborations, and white paper driven proof of value for large customers.

Global Lab Services GCP-compliant laboratories in the UK and US enable scalable CLIA-like services for pharma and biotech sponsors. Opportunities exist to expand global service footprints, offer turnkey assay development, and provide end-to-end sample processing for multinational clinical trials.